Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.24.1.1.u2
Condensed Consolidated Statements of Operations (Unaudited) - GBP (£)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development expenses £ 1,298,942 £ 1,934,304
Administrative expenses 2,142,714 2,231,461
Total operating expenses 3,441,656 4,165,765
Loss from operations (3,441,656) (4,165,765)
Other income (expense):    
Change in fair value of derivative liability 11,446 3,148,648
Other expense, net (2,386) (17,794)
Total other income (expense), net 9,060 3,130,854
Net loss before income taxes (3,432,596) (1,034,911)
Income tax credit 110,742 400,000
Net loss £ (3,321,854) £ (634,911)
Weighted-average ordinary shares outstanding - basic 30,138,602 2,051,836
Weighted-average ordinary shares outstanding - diluted 30,138,602 2,051,836
Basic net loss per share £ (0.11) £ (0.31)
Diluted net loss per share £ (0.11) £ (0.31)